We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Big-name drug companies have already increased their list prices for more than 300 brand-name drugs in the new year, marking another year of early January price hikes. Read More
Novo Nordisk launched half-priced generic versions of NovoLog and NovoLog Mix in the U.S. Tuesday, aiming to provide cheaper insulin products. Read More
2019 was one of the biggest years on record for pharma mergers and acquisitions, including the third largest acquisition of all time — Bristol-Myers Squibb’s $74 billion acquisition of Celgene. Read More
Walgreens and other big name retailers have filed an antitrust suit against Bausch Health, its subsidiaries, and generic drugmaker Lupin for allegedly plotting to hike the price of Bausch’s diabetes drug Glumetza and Lupin’s generic version. Read More
Novartis has forged a merger agreement with The Medicines Company under which it will buy up the firm’s cholesterol drug inclisiran for a whopping $9.7 billion. Read More
CDER Director Janet Woodcock said an agency task force supports a new rating system designed to inform purchasers about drug facilities with higher reliability. Read More
The plaintiffs failed to comply with court directives to submit documentation supporting their claims and to show they used the brand name version of Abilify. Read More
Otsuka subsidiary Avanir Pharmaceuticals agreed to pay approximately $116 million to settle whistleblower fraud allegations that the company offered kickbacks to doctors and salespeople to push Nuedexta off label for dementia patients. Read More
A federal judge in Florida has thrown out 149 lawsuits in multidistrict litigation alleging Abilify (aripiprazole) caused their compulsive behavior. Read More
JHL Biotech has conceded to Genentech in a lawsuit over JHL’s development of biosimilars, to settle claims that it used stolen trade secrets to develop copycat drugs. Read More